Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer

• DOI: 10.1007/s10549-020-05746-8
• Publication Date: 2020-07-01T09:40:41Z
• Authors: Vincent Walter; Chiara Fischer; Thomas M. Deutsch; Catherine Ersing; Juliane Nees; Florian Schütz; Carlo Fremd; Eva-Maria Grischke; Peter Sinn; Sara Y. Brucker; Andreas Schneeweiss; Andreas D. Hartkopf; Markus Wallwiener
• Keywords: Progesterone receptor; Primary tumor

Abstract Background The estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) statuses are frequently discordant between the primary tumor metastatic lesions in breast cancer. This can have important therapeutic implications. Patients methods In all, 541 patients with available from both lesion treated at Heidelberg Tuebingen University Hospitals 1982 2018 were included. Results Statistically significant discordance rates of 14% 32% found for ER PR. HER2 status was statistically insignificantly 15% patients. Gain positivity associated an improved overall survival, whereas loss HR worse survival. Antiendocrine treatment differed 20% cases before after biopsy HER2-directed cases. Conclusions Receptor metastasis a considerable fraction Next to highly presumed predictive value respect efficacy endocrine HER2-targeted therapy, seems provide prognostically relevant information. Where feasible, should be biopsied accordance current guidelines.